ORTHOCELL LIMITED — Director's Dealing 2022

Nov 22, 2022

Appendix 3Y Change of Director’s Interest Notice

fRule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lars Lidgren
Date of last notice	11/11/2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Part 1 - ChangIn the case of a trusNote: In the case of ain this part	Part 1 - ChangIn the case of a trusNote: In the case of ain this part	e of director’s relevant intet, this includes interests in the trustcompany, interests which come within pa	rests in securitiesmade available by the responsible enragraph (i) of the definition of “notifiable i	rests in securitiesmade available by the responsible enragraph (i) of the definition of “notifiable i	tity of the trustnterest of a director”	should be disclosed	should be disclosed
.Direct or inNature of in(including rNote: Provide deinterest.
	Direct or in	direct interest		Direct and In	direct
	Nature of in(including rNote: Provide deinterest.	direct interestegistered holder)tails of the circumstances giving rise	to the relevant	Algora AB heldBanque Carne(Professor Lid	bygie Swedengren is a direc	tor of Algora A	B)
	Date of change
	No. of securities held prior to changeAlgora AB held by Carnegie Investment BankAB viaJP Morgan Nominees Australia LimitedAlgora AB Sweden			365,344 Ordinary Shares915,716 Ordinary Shares500,000 Unlisted Options exercisable at $0.617expiring 20 November 2022500,000 Unlisted Options exercisable at $0.583expiring 14 October 2024
	Class			Unlisted Options
	Number acquired			-
	Number disposed			500,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	-
No. of securities held after changeAlgora AB held by Carnegie Investment BankAB viaJP Morgan Nominees Australia LimitedAlgora AB	365,344 Ordinary Shares915,716 Ordinary Shares500,000 Unlisted Options exercisable at $0.583expiring 14 October 2024
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

in thispart.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interestrelated prior to changeNote: Details are only required for a contract in relation to which the interesthas changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period?

• See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was provided, on what date N/A was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 3